Shifting PrEP Initiation from Practitioner to Nurse: a clinic-level multi-modal intervention protocol to increase PrEP uptake among women at increased risk of HIV acquisition in a U.S. OB/GYN clinical setting

Setting

This project will be launched in three OB/GYN outpatient clinics of a single academic medical system in Baltimore, Maryland, which has a Black majority population and a poverty rate of over 20% (U.S. Census Bureau, n.d.). In 2018, Baltimore City had an estimated HIV incidence rate of 42.1 per 100,000 population (CDC, 2020). It is one of the 57 jurisdictions targeted in the EHE Initiative (HIV.gov, 2020). The clinics offer general obstetric and gynecologic care, with some providing specialized care for high-risk pregnancies. We selected an outpatient OB/GYN setting because it is where women routinely receive STI counseling, testing, and treatment. Data has shown that STIs increase the risk of HIV acquisition and transmission (Ward & Rönn, 2010). Furthermore, HIV incidence among pregnant and postpartum women is 2-4 times higher than the rates outside of pregnancy, likely due to behavioral and biological changes during this time period (Mugo et al., 2011; Thomson et al., 2018). Therefore, regularly scheduled obstetric and annual gynecologic visits are opportunities for healthcare practitioners to discuss sexual health and HIV-risk behaviors with patients.

Patients

Patients will be included in the project if they are assigned female at birth, not living with HIV, and are receiving OB/GYN care in our preselected clinics. Obstetric patients will be identified through an existing non-validated STI/HIV risk assessment tool embedded into our electronic medical record (EMR) (Table 1), which is completed by an RN during a patient’s initial prenatal care visit. This tool was developed over a decade ago as part of general behavioral risk assessment for obstetrics patients, and not specifically for PrEP eligibility.

Eligible gynecologic patients will be identified by a positive STI diagnosis within the past 6 months, or if seeking STI testing and have a history of an STI (either self-reported or resulted in the EMR). Because PrEP eligibility criteria (Table 2) differ by guidelines and expert opinion, we selected broad criteria given the high HIV prevalence in our area (U.S. Public Health Service, 2018; The American College of Obstetricians and Gynecologists [ACOG], 2014). Before PrEP is prescribed, PrEP contraindications will be followed, including: symptoms or clinical signs consistent with acute HIV infection, unknown HIV infection status, allergies to the active substances or any excipients of PrEP, estimated creatinine clearance of <60 mL/minute, active Hepatitis B infection, or are participating in other clinical studies related to HIV and/or antiretroviral therapy.

Study design

The study is designed with several, sequential methodologic components because of our organizational culture and prior data that suggest complex, multi-level barriers to PrEP uptake among women. First, we will synthesize the existing literature, engage key stakeholders, and conduct microlearning sessions about PrEP. Microlearning sessions involve the delivery of educational content that is brief, targeted, and occur within clinical sites (Buchem & Hamelmann, 2010). Microlearning sessions will be conducted among all healthcare team members in the clinic, which includes nurses, medical assistants, nurse practitioners, midwives, and physicians. Then, Plan-Do-Study-Act (PDSA) will be used. The PDSA method is a commonly used improvement process in health care settings, which utilizes small tests of change to optimize a process (Coury et al., 2017). A common misperception with PDSA methodology is that it is a standalone method (Reed & Card, 2016). Therefore, we designed multiple rigorous methodologies to include along with PDSA.

The first PDSA cycle will involve EMR changes and identification of a registered nurse (RN) who will be trained to initiate PrEP. Our prior data has shown that PrEP is rarely discussed or prescribed to patients, despite indications (Fruhauf & Coleman, 2017; Lopez et al., 2019). Proposed EMR changes will include the creation of (1) Best practice alerts (BPAs) that encourage nurses and practitioners to add HIV risk-related ICD-10 codes to the problem lists. Problem lists contain a summary snapshot of the patient’s medical conditions for use by all practitioners. A positive risk screen for prenatal care patients will alert the nurse to add “HIV risk factors complicating pregnancy” to the patient’s problem list during the initial prenatal visit. When a patient tests positive for an STI and is prescribed an antibiotic for treatment, a BPA will alert the GYN practitioner that the patient may have HIV acquisition risk factors and to add “encounter for HIV counseling” to the problem list; (2) Comprehensive and easily accessible order sets that facilitate initiation of PrEP by outlining the required laboratory tests and their timing, and the exact FTC/TDF medication instructions to avoid incorrect prescriptions; (3) Note templates that allow for consistent documentation and serve as an educational tool to ensure adequate HIV prevention counseling is complete; (4) PrEP patient educational material to include in patient after-visit summaries, which are given to patients at the conclusion of clinic appointments. Educational materials include frequently asked questions (FAQ), FTC/TDF medication facts, and PrEP use during pregnancy or breastfeeding; and (5) short animation videos that describe PrEP.

We will identify a PrEP-RN who will undergo training in HIV prevention, including the use of PrEP. Well within the scope of nursing practice, RNs can screen patients for risk factors, counsel and educate at-risk patients about effective HIV prevention strategies, and advocate for PrEP utilization. To our knowledge, this is the first U.S. RN-led PrEP program for women exclusively. One novel aspect of our program is that our PrEP-RN will be able to initiate laboratory test ordering and PrEP prescriptions, under specific protocol guidance and supervision by the clinic’s Medical Director. Another innovative aspect is that we designed our PrEP-RN program to allow for telehealth counseling sessions for initiation and follow-up sessions via telephone or video. Patients are only required to visit a brick-and-mortar location to complete laboratory tests, which can take place at a location most convenient for them.

Other models for RN-led PrEP programs have been developed in Canada, but none focus exclusively on women, take place in an OB/GYN outpatient setting where women prefer to receive information about HIV prevention, or allow telehealth (Auerbach et al., 2015; Hirschhorn et al., 2020; Sharma et al., 2018). As O’Byrne highlights in their PrEP-RN model, the numerous appointments involved with the first year of PrEP use has a high potential for missed appointments, which may be remedied by the use of telehealth (O’Byrne et al., 2019).

The second PDSA cycle will incorporate feedback from the first cycle and then deploy the PrEP-RN intervention at the main outpatient clinic site. Subsequent PDSA cycles will include roll-out of the project at the remaining clinical sites with protocol adjustments, as needed based on the prior PDSA cycle. To test whether an RN can effectively counsel patients about PrEP, initiate therapy, and follow patients with minimal practitioner involvement, we plan to conduct a pragmatic randomized controlled trial (RCT). A pragmatic (effectiveness) trial was selected to generate evidence that would be applicable in a real-world clinical practice setting and increase external validity. The control arm will include an enhanced standard of care (e-SOC), which is standard of care plus the EMR changes. The intervention arm will include the PrEP-RN plus e-SOC.

Patients randomized to the intervention arm will first be contacted via an electronic patient portal integrated with the EMR that allows patients access to their medical records and a messaging system to communicate with practitioners. While most of our patients utilize this patient portal, if a patient does not have access, this step will be skipped.

Follow-up telephone calls will then be made to counsel patients on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP. PrEP, including same-day PrEP, will be offered. If the required laboratory tests have not been obtained in the past month, the PrEP-RN will place and order the laboratory tests. The PrEP-RN will utilize the PrEP order set in the EMR to order labs, prescribe medication electronically to the patient’s pharmacy, provide patient education, and schedule follow-up appointments. All orders and prescriptions are sent to the clinic’s Medical Director for authorization. Standardized smartphrases for clinical notes will also be utilized to record the interaction by the PrEP-RN with the study participants.

If a patient declines PrEP, no further attempts are made by the PrEP-RN to counsel the patient. Additional educational material may be sent via the electronic patient portal as desired by the patient. The patient is encouraged to contact the PrEP-RN, via telephone or the electronic patient portal, if she has any future questions or decides to use PrEP.

A Manual of Procedures (Appendix A) was created for the PrEP-RN to carry out each step of PrEP initiation and follow up. The manual outlines how to respond to abnormal tests, provide prescription coverage assistance, and coordinate care with other specialties as needed to address test results. The PrEP-RN will be responsible for follow-up visits and will contact the patients one-two weeks after medication initiation. At this time, the PrEP-RN will review the importance of daily adherence to PrEP and assess for any side effects.

Randomization and blinding

Stratified block randomization will be used to allocate eligible patients into the intervention and control arms with a 1:1 ratio. Patients will be classified by patient type (obstetric or gynecologic) and clinics. To avoid imbalance between the two study arms, the same type of patients from the same site will be randomized within a block that comprise four ordered assignments. SAS will be used to generate the randomization table. EMR data abstracts will be obtained biweekly to identify PrEP eligible patients. A member of the study team will assign these PrEP eligible patients to an intervention arm based on the randomization allocation per patient type and site. Practitioners will be blinded to study assignment to prevent interference in the standard of care delivery.

Ethics Approval and Waiver of Consent to Participate

The study received approval from the Institutional Review Board (IRB) of Johns Hopkins Medicine. Although the primary purpose of the project was to improve patient outcomes, the IRB reviewed the project as research because we included randomization plus an external funding source. However, a waiver of consent was granted because the study involves no more than minimal risk to the subjects, the waiver does not adversely affect the rights or welfare of the subjects, and the research could not be practicably completed without the waiver.

Sample size estimate

To test the effectiveness of the PrEP-RN, we estimate that we will require 440 patients (220 women per arm). The sample size was selected to provide 80% power to detect an effect size of 15% between the control and intervention group, at an alpha level of 0.05 using two-sided test. The PrEP-RN intervention and EMR prompts will cease once the sample size has been reached.

Primary Outcomes

The primary outcome estimated by the RCT will be awareness of PrEP, measured by the percentage of at-risk women with EMR documentation of HIV risk prevention counseling.

Secondary Outcomes

Secondary outcomes will include feasibility, which will be defined as reaching the target goal in at least 3 of the RE-AIM domains (Table 3). Other secondary outcomes include the percentage of women at risk for HIV who initiate PrEP during the study interval and the percentage of women who are using PrEP at 3-, 6-, 9-, and 12-months from initiation. PrEP initiation will be measured by the number of PrEP laboratory tests and the number of PrEP prescriptions ordered. We will also assess the utilization of EMR enhancements, measured as the percentage of patients with an HIV-risk diagnosis added to their EMR problem list. Last, we will evaluate the acceptability of the PrEP-RN intervention among our study population.

Acceptability

Acceptability of and satisfaction with the PrEP-RN intervention will be evaluated using a brief survey of a randomly selected group of patients (n=25) who received the PrEP-RN intervention within the previous three months (Table 4). Items related to patient satisfaction and telehealth acceptability were identified through a review of the literature (Weaver et al., 2021; Yip et al., 2003; Gwadry-Sridhar et al., 2003).

Risks and monitoring

The intervention does not pose any greater risks than routine clinical care, and no participant will receive less than e-SOC. Because the intervention is integrated at the clinic level and poses minimal risk, we do not have an independent data monitoring committee. The team will report any adverse events to the IRB. To ensure the quality of our counseling intervention, we will have weekly check-ins with the PrEP RN, research staff, and the study Principal Investigator to discuss any issues in counseling patients and incorporate patient feedback on an ongoing basis.